{"schemaVersion":"ready-scan.discovery-surface.v1","id":"urn:readyscan:corpus:buyer-question:regenold-gmbh-q140571087-answer-4ee5241047a65dad957c","key":"buyer_question:regenold-gmbh-q140571087-answer-4ee5241047a65dad957c","kind":"buyer_question","slug":"regenold-gmbh-q140571087-answer-4ee5241047a65dad957c","canonicalUrl":"https://directory.readyscan.ai/corpus/buyer-question/regenold-gmbh-q140571087-answer-4ee5241047a65dad957c","machineUrl":"https://directory.readyscan.ai/discovery/corpus/buyer-question/regenold-gmbh-q140571087-answer-4ee5241047a65dad957c.json","datePublished":"2026-10-26","dateModified":"2026-10-26","materialFingerprint":"fnv1a64:614a74de756aacc2","membershipFingerprint":"fnv1a64:ebfa9a6744ac32d8","relatedEntitySlugs":["regenold-gmbh-q140571087"],"relatedSurfaceKeys":["buyer_question:regenold-gmbh-q140571087-answer-37a711685e2365c3a89f","buyer_question:regenold-gmbh-q140571087-answer-37f1dca73a0e057e757e","buyer_question:regenold-gmbh-q140571087-answer-4591d5048634f515fd4b","buyer_question:regenold-gmbh-q140571087-answer-498842324866f417c390","buyer_question:regenold-gmbh-q140571087-answer-4b02d27790070848d2d9","buyer_question:regenold-gmbh-q140571087-answer-518e5a634038e207425b","buyer_question:regenold-gmbh-q140571087-answer-58e1a9f02c93d9d42247","buyer_question:regenold-gmbh-q140571087-answer-6d349f787f5c4fa379d6","buyer_question:regenold-gmbh-q140571087-answer-9aed178f2fe661510ed2","buyer_question:regenold-gmbh-q140571087-answer-9eae8d071e1ec8a20afa","buyer_question:regenold-gmbh-q140571087-answer-a226a9a6037046c1549a","buyer_question:regenold-gmbh-q140571087-answer-ad0e76bb92db40823d71","buyer_question:regenold-gmbh-q140571087-answer-ddcfce807ca92b72ecfd","buyer_question:regenold-gmbh-q140571087-answer-e1389031ab82135145ac","buyer_question:regenold-gmbh-q140571087-answer-ec6f98f6761598e4f43e","buyer_question:regenold-gmbh-q140571087-answer-f284b044f7926ab6dbda","buyer_question:regenold-gmbh-q140571087-answer-f34785f5ae19196605b7","evidence:regenold-gmbh-q140571087"],"sourceIds":["ready-scan-subjects"],"provenance":[{"snapshotId":"regenold-gmbh-q140571087-content-616544846ed4eda7-snapshot","sourceId":"ready-scan-subjects","sourceRecordId":"Q140571087","sourceRevisionId":"Q140571087:content:42d5154a2e8358d1","sourceContentHash":"fnv1a64:88817713b3e21398","recordRevisionId":"Q140571087:content:42d5154a2e8358d1","recordContentHash":"fnv1a64:03e35b32ff7e009f","sourceCanonicalUrl":"https://regenold.com/","sourceModifiedAt":"2026-10-26T12:36:16.052Z","observedOn":"2026-10-26","permission":{"basis":"public_information","evidenceUrl":"https://regenold.com/"},"attributionUrl":"https://regenold.com/"}],"quality":{"method":"same_kind_unique_trigram_floor","minimumUniqueTrigramRatio":0.3,"status":"passed"},"title":"How has ICH E6(R3) changed how you design trials?","summary":"Cited source answers across 1 active corpus record.","question":"How has ICH E6(R3) changed how you design trials?","answers":[{"entitySlug":"regenold-gmbh-q140571087","entityName":"regenold GmbH","answer":"“ICH E6(R3) was finalised in January 2025 and became effective in the EU in July 2025. The biggest practical changes are the emphasis on quality by design (identifying “critical to quality” factors upfront), proportionate monitoring (risk-based rather than 100% source data verification), and formal recognition of decentralised trial elements (remote consent, home delivery of IMP, wearable data capture).”","sourceUrls":["https://regenold.com/services/clinical-development"]}]}